

Versican Plus P lyophilisate and solvent for suspension for injection for dogs

Authorised

- Canine parvovirus 2b, strain CPV-2b Bio 12/B, Live

Product identification

Medicine name:

Versican Plus P lyophilisate and solvent for suspension for injection for dogs
VERSICAN PLUS P

Active substance:

Canine parvovirus 2b, strain CPV-2b Bio 12/B, Live

Target species:

Dog

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Canine parvovirus 2b, strain CPV-2b Bio 12/B, Live
3981070.00 tissue culture infective dose 50 / 1.00 Dose

Pharmaceutical form:

Lyophilisate and solvent for suspension for injection

Withdrawal period by route of administration:

Subcutaneous use:

- **Dog**

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AD01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Italy

Package description:

Available only in Italian

Available only in Italian

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)

Marketing authorisation holder:

Zoetis Italia S.r.l

Marketing authorisation date:

24/06/2016

Manufacturing sites for batch release:

Bioveta a.s.

Responsible authority:

Ministry Of Health

Authorisation number:

104899

Date of authorisation status change:

24/06/2016

Reference member state:

Germany

Procedure number:

DE/V/0265/001

Concerned member states:

Belgium Bulgaria Croatia Cyprus France Greece Hungary Ireland Italy
Luxembourg Malta Romania Slovenia United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 24/05/2023

[Download](#)

Source URL: <https://medicines.health.europa.eu/veterinary/600000063126>